Department of Oral and Maxillofacial Surgery, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.
Clin Oral Implants Res. 2012 Mar;23(3):263-73. doi: 10.1111/j.1600-0501.2011.02168.x. Epub 2011 Mar 28.
The objective of the present systematic review was to test the hypothesis of no differences in the implant treatment outcome when Bio-Oss or Bio-Oss mixed with autogenous bone is used as graft for the maxillary sinus floor augmentation (MSFA) applying the lateral window technique.
A MEDLINE (PubMed) search in combination with a hand search of relevant journals was conducted by including human studies published in English from January 1, 1990 to June 1, 2010. The search provided 879 titles and 35 studies fulfilled the inclusion criteria. Considerable variation in the included studies prevented meta-analysis from being performed and no long-term study comparing MSFA with the two treatment modalities was identified. Also, the survival of suprastructures after the two augmentation procedures was not compared within the same study.
The 1-year implant survival was compared in one study demonstrating no statistically significant difference. The implant survival was 96% with Bio-Oss and 94% with a mixture of 80% Bio-Oss and 20% autogenous mandibular bone. Addition of a limited amount of autogenous bone to Bio-Oss seemed not to increase the amount of new bone formation and bone-to-implant contact compared with Bio-Oss.
Therefore, the hypothesis of no differences between the use of Bio-Oss or Bio-Oss mixed with autogenous bone as graft for MSFA could neither be confirmed nor rejected.
本系统评价的目的是检验这样一个假设，即在应用外侧壁开窗技术行上颌窦底提升术（MSFA）时，使用 Bio-Oss 或 Bio-Oss 混合自体骨作为移植物，其在种植体治疗效果方面没有差异。
通过检索 1990 年 1 月 1 日至 2010 年 6 月 1 日期间发表的英文文献，结合对相关杂志的手工检索，我们进行了 MEDLINE（PubMed）搜索。该检索共提供了 879 个标题，其中 35 项研究符合纳入标准。由于纳入的研究存在较大差异，因此无法进行荟萃分析，也没有发现比较两种治疗方式的长期 MSFA 研究。此外，在同一研究中，也没有比较两种增强程序后上部结构的存活率。
有一项研究比较了 1 年的种植体存活率，结果显示无统计学意义的差异。Bio-Oss 组的种植体存活率为 96%，Bio-Oss 混合 80%自体下颌骨和 20%自体骨组的存活率为 94%。与单独使用 Bio-Oss 相比，向 Bio-Oss 中添加少量自体骨似乎并没有增加新骨形成和骨-种植体接触的量。
因此，不能证实或排除 Bio-Oss 或 Bio-Oss 混合自体骨作为 MSFA 移植物在使用方面没有差异的假设。
